Galecto, Inc.

Headquarters: Copenhagen, Denmark

Employees: 28

CEO: Dr. Hans T. Schambye

show_chart NASDAQ: GLTO -1.71%

Market Cap

$65.5 Million

USD as of July 1, 2023

history Market Cap History

Galecto, Inc. market capitalization over time

Evolution of Galecto, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Galecto, Inc.

Detailed Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Stocks & Indices

Galecto, Inc. has the following listings and related stock indices.




Ole Maaloes Vej 3

Copenhagen N

Copenhagen, 2200


Phone: 45 70 70 52 10